Clear cell adenocarcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A malignant neoplasm composed of glandular epithelial clear cells. Various architectural patterns may be seen, including papillary, tubulocystic, and solid.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Clear cell adenocarcinoma
- Therapeutic area
- Oncology
- clear cell adenocarcinoma
- adenocarcinoma, clear cell, malignant
- clear cell adenocarcinoma (morphologic abnormality)
- clear cell adenocarcinoma NOS (morphologic abnormality)
- mesonephroma NOS (morphologic abnormality)
- water-clear cell adenocarcinoma (morphologic abnormality)
- All therapeutic areas
- Oncology
Sources for recorded values
- Severity
- Severe
- MONDO ID
- MONDO:0005004
- Parent condition
- MONDO:0004970
Related records
Broader conditions (11)
- Adenocarcinoma
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by etiologic mechanism
- Epithelial neoplasm
- Glandular cell neoplasm
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (20)
- Ampulla of vater clear cell adenocarcinoma
- Bladder clear cell adenocarcinoma
- Bladder diffuse clear cell adenocarcinoma
- Bladder papillary clear cell adenocarcinoma
- Bladder tubulo-cystic clear cell adenocarcinoma
- Cervical clear cell adenocarcinoma
- Clear cell renal carcinoma
- Endometrial clear cell adenocarcinoma
- Extrahepatic bile duct clear cell adenocarcinoma
- Fallopian tube clear cell adenocarcinoma
- Glycogen-rich clear cell breast carcinoma
- Hepatocellular clear cell carcinoma
- Hereditary clear cell renal cell carcinoma
- Hidradenocarcinoma
- Multilocular clear cell renal cell carcinoma
- Ovarian clear cell adenocarcinoma
- Ovarian clear cell cystadenocarcinoma
- Urethra clear cell adenocarcinoma
- Uterine ligament clear cell adenocarcinoma
- Vulvar clear cell hidradenocarcinoma
Trials (56)
- A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
- A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
- A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers
- A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
- A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
- A Study of Nivolumab in Selected Uterine Cancer Patients
- A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
- A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
- A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
- AMT-151 in Patients With Selected Advanced Solid Tumours
- An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
- APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
- Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
- Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
- Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
Drugs in development (14)
- Axitinib Phase 2
- Bevacizumab Phase 2
- Carboplatin Phase 2
- Dostarlimab Phase 1
- Durvalumab Phase 2
- ENMD-2076 Phase 2
- LB-100 Phase 1
- Metformin Phase 1
- Metformin hydrochloride Phase 1
- Paclitaxel Phase 2
- Risovalisib Phase 2
- Sintilimab Phase 2
- Toripalimab Phase 2
- Zimberelimab Phase 1